Myopathies: an endocannabinoid signature identified in muscles, without evidence of therapeutic benefit

The endocannabinoid system shows shared changes in muscles affected by different myopathies, according to a meta-analysis of human data. But this observation concerns gene expression: it demonstrates neither the cause of muscle degeneration nor the value of a treatment targeting this system.

Illustration of muscle tissue and endocannabinoid system genes studied in myopathies.
TrainingEditorial illustration, not study data.

Data from muscle biopsies

The researchers reanalyzed public RNA sequencing datasets from 328 muscle biopsies of patients with myopathies and 173 control samples. Several diseases were represented, including Duchenne and Becker muscular dystrophies, myotonic dystrophy type 1, and inflammatory myopathies.

The aim was to look for differences in the expression of genes associated with endocannabinoid system receptors and enzymes. Preclinical research implicates this system in muscle inflammation, regeneration, and metabolism. However, these mechanisms are not enough to establish its role in patients.

Two changes shared across several diseases

The analysis finds generally higher expression of CNR1, the gene encoding cannabinoid receptor type 1, and lower expression of FAAH. This enzyme helps break down anandamide and other molecules in the N-acylethanolamine family.

These differences persist after adjustment for sex and with other analytical models. CNR1 also shows the lowest heterogeneity among the genes studied. By contrast, changes in enzymes involved in 2-arachidonoylglycerol metabolism depend more on the disease in question.

A biological signature, not a validated therapeutic target

The finding concerns RNA measured in biopsies. It does not directly demonstrate an increase in functional receptors, a decrease in enzyme activity, or a change in endocannabinoid concentrations. The authors hypothesize altered functioning of this system, which remains to be characterized.

This retrospective analysis also cannot determine whether these changes contribute to muscle damage, result from it, or accompany an adaptive response. It does not measure the effectiveness of an intervention on strength, mobility, or the progression of myopathies.

So you cannot conclude that a product acting on the endocannabinoid system would protect muscles. Instead, the authors call for combining endocannabinoid measurements with clinical data tracked over time to clarify what this signature means.

Limitations to keep in mind

Only the supplied PubMed abstract was consulted, not the full text. The analysis relies on retrospective RNA data from whole biopsies and demonstrates neither causality nor clinical benefit. Funding and conflicts of interest cannot be verified from the available excerpt.

What we can take away

Several myopathies share changes in endocannabinoid system gene expression. This is a lead for understanding these diseases, not a demonstration of therapeutic benefit.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.